NCT03177278 is a Phase 1 clinical trial of [14C]-plazomicin in Healthy Volunteers, sponsored by Achaogen, Inc..

Who is sponsoring NCT03177278?

NCT03177278 is sponsored by Achaogen, Inc..

What drugs are being tested in NCT03177278?

Interventions in NCT03177278: [14C]-plazomicin.

What condition does NCT03177278 study?

NCT03177278 studies Healthy Volunteers.

Is NCT03177278 still recruiting?

NCT03177278 is currently completed. Last updated 12 July 2017.

Last reviewed 2017-07-12 · How we verify

NCT03177278

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin

Completed Phase 1 Last updated 12 July 2017

What this trial tests

Phase 1 trial testing [14C]-plazomicin in Healthy Volunteers in 6 participants. Completed in 10 July 2017.

Timeline

16 June 2017

Primary endpoint
10 July 2017

10 July 2017

Quick facts

Lead sponsor	Achaogen, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	16 June 2017
Primary completion	10 July 2017
Estimated completion	10 July 2017
Sites	1 location across United States

Drugs / interventions tested

[14C]-plazomicin — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Achaogen, Inc. — full company profile →

Who can join

Adults 19 to 55, male only, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open label, non-randomized metabolism, excretion, and mass balance study of a single IV infusion of \[14C\]-plazomicin in healthy, adult male subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance.
Clark JA, Burgess DS. · · 2020 · cited 40× · PMID 32953108 · DOI 10.1177/2049936120952604
Plazomicin against Multidrug-Resistant Bacteria: A Scoping Review.
Alfieri A, Di Franco S, Donatiello V, Maffei V, et al · · 2022 · cited 21× · PMID 36556314 · DOI 10.3390/life12121949

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Achaogen, Inc. trials

Trials by the same sponsor.

NCT03270553 — A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin · Phase 1 · completed
NCT03163550 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-3 · Phase 1 · completed
NCT02486627 — A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including · Phase 3 · completed
NCT01970371 — A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae ( · Phase 3 · completed
NCT01096849 — A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acu · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03177278 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Achaogen, Inc.
Last refreshed: 12 July 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03177278.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing